Reference is made to the stock exchange announcement published by Lifecare ASA (the "Company") on 7 January 2026, regarding the commencement of the subscription period in the partially underwritten rights issue (the "Rights Issue").

In connection with the Rights Issue, subscription rights have been allocated to existing shareholders as of 2 January 2026 (record date 6 January 2026), based on their registered shareholdings in the Company. Each existing share entitled the holder to 10.49 subscription rights, rounded down to the nearest whole subscription right. Each subscription right gives the right to subscribe for and be allocated one (1) new share in the Rights Issue at a subscription price of NOK 0.50 per share.

Subscription rights have been allocated to the following primary insiders and/or persons closely associated with them:

• Teigland Eiendom AS, a company closely associated with Trine Teigland, board member of the Company, has been allocated 23,100,406 subscription rights.
• Hannibal Invest AS, a company closely associated with Hans Hekland, board member of the Company, has been allocated 187,739 subscription rights.
• Tone Kvåle, board member of the Company, has been allocated 48,421 subscription rights.
• Joacim Holter, CEO of the Company, has been allocated 236,434 subscription rights.
• Cimter AS, a company closely associated with Joacim Holter, CEO of the Company, has been allocated 941,718 subscription rights.
• Islay Venture GmbH, a company closely associated with Andreas Pfützner, CSO of the Company, has been allocated 1,410,747 subscription rights.

The allocation of subscription rights is made automatically and free of charge to existing shareholders in accordance with the terms of the Rights Issue and does not involve any consideration paid by the recipients.

Following the allocation of subscription rights, the shareholdings of the above-mentioned primary insiders and/or their closely associated persons remain unchanged.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-01-07 09:44 CET.

Attachments
Lifecare ASA: Mandatory notification of trade – allocation of subscription rights

Läs mer på MFN